Lead Product

Lead Product

Phagelux Lead Products are Designed to Prevent or Treat Ulcer-induced Infections

The Disease

Pressure ulcers are common in hospitals and long-term care facilities. The incident rates vary widely due to multiple factors but can be anyplace between 8.3% and 26% of all long-term patients. While normally regarded by most care facilities as a nuisance problem, in fact in 1990 about 14,000 people worldwide died from infections that started with bed sores. By 2013, this number had increased to 29,000 with the increase often associated with a drug resistant pathogen. It is reported that 39.7% of sepsis deaths started from an ulcer infection.  In addition, large medical expenditures result from the onset of an infection (around $5 billion USD are incurred annually for the treatment of pressure ulcer related infections). Therefore preventing and treating pressure ulcer related infections, especially drug-resistant pathogens, is an increasingly important area of science.

The Phagelux Solutions

Phagelux has developed a slow-release technology that allows bacteriophages to be released over time to prevent infections. Phagelux products come in both spray and patch formulations. The Spray-Patch utilizes a biodegradable co-polymer (polyester amide urea based in amino-acid frame) to microencapsulate a phage cocktail in a manner that allows for the slow and continuous release of phages. Utilizing similar technology, the ProPatch is a biodegradable thin film that also slowly releases a phage cocktail. The Pro-Patch can be sterilized (Phagelux has filed for a patent on how to sterilize a phage product). The advantages of both technologies include: slow and steady sustained release, long-term efficacy, long-term storage at room temperature, low cost, and very easy to use. The products enjoy multiple patent protections.

Developing Novel Antibiotics Requires Novel Technology and Novel Business Models

As antibiotic resistance grows the world needs for many new antibiotics.  But, healthcare systems want to use new antibiotics as last resort which means for the developers that few patients will actually use.  One key difference for phages is that it looks like regulators around the globe will allow phage products to be updated if resistance to the product is later found.  No new drug filing will be required (rather like a flu vaccine that is frequently updated).  This will allow our product to be used as a first line treatment since there is no need to worry about antibiotic resistance.  Our products will also be relatively inexpensive making them appropriate for use for all pressure ulcer patients (and later wound care and mild burn care patients).  Finally, we believe that the use of our products, and the corresponding reduction of infections, will reduce costs for hospitals.  In other words, by reducing infections the hospital will save money.



Both 14-phage products are designed to prevent AMR infections in patients that have experienced a bed sore (pressure ulcer).